A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Robinson, Hannah R., Qi, Junpeng, Cook, Erika M., Nichols, Cydney, Dadashian, Eman L., Underbayev, Chingiz, Herman, Sarah E. M., Saba, Nakhle S., Keyvanfar, Keyvan, Sun, Clare, Ahn, Inhye E., Baskar, Sivasubramanian, Rader, Christoph, Wiestner, Adrian
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073325/
https://ncbi.nlm.nih.gov/pubmed/29743179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-830992
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars